Incyte Profit Margin 2006-2021 | INCY
Current and historical gross margin, operating margin and net profit margin for Incyte (INCY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Incyte net profit margin as of June 30, 2021 is 12.41%.
|Incyte Annual Profit Margins
|Incyte Quarterly Profit Margins
||Medical - Biomedical and Genetics
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. They have a diverse and growing portfolio of product candidates, including both small and large molecules.